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 High density lipoprotein (HDL) is an atheroprotective element which is critical in 
the reverse cholesterol transport (RCT) pathway to eliminate excess cholesterol from the 
periphery of the body. A low plasma HDL cholesterol levels indicate a higher risk of 
getting cardiovascular diseases (CVD). Formation and metabolism of HDL largely rely 
on ATP binding cassette transporter A1 (ABCA1) and G1 (ABCG1) that are transporters 
to facilitate the efflux of cellular cholesterol to outside of cells. ABCA1 in the liver and 
small intestine is the major contributing factor for HDL formation. On the other hand, 
ABCA1 and ABCG1 present in macrophages contribute to cellular cholesterol 
homeostasis and protection against foam cell formation in artery. The objective of the 
study was to elucidate the regulatory mechanism for the expression of ABCA1 and 
ABCG1by fatty acids in HepG2 (a human hepatoma cell line), FHs 74 Int (a human small 
intestine epithelial cell line) and RAW264.7 macrophages. In all these cell lines, 
unsaturated fatty acids, but not saturated fatty acids, repressed the expression of ABCA1 
and ABCG1 at the transcriptional and/or post-transcription levels in a cell type specific 
manner. The results of this study suggest the following mechanisms for the repressive 
effect of unsaturated fatty acids on the ABCA1 and ABCG1 expression: 1) ABCA1 in 
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HepG2 and FHs 74 Int cells is inhibited by unsaturated fatty acids at the post-
transcriptional level via calpain-independent mechanism; 2) ABCA1 and ABCG1 in 
RAW264.7 macrophages are repressed by unsaturated fatty acids at the transcriptional 
level by a liver X receptor-dependent mechanism and at the post-transcriptional level by 
increasing protein degradation.  
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Introduction 
 
 
Type 2 Diabetes is one of the deadliest diseases in the United States, affecting 8% 
or 17.9 million people in 2008 while another 57 million are at the border line of diabetes 
according to American Diabetes Association. Among the complications of diabetes, 
cardiovascular disease (CVD) is the top leading cause of morbidity and mortality in the 
diabetic subjects [1, 2]. Inverse relationship between plasma high density lipoprotein 
(HDL) cholesterol concentrations and the CVD risk has been reported in many human 
studies, indicating that plasma HDL is an atheroprotective element [3, 4]. HDL removes 
excess cholesterol from the peripheral tissues to the liver for ultimate excretion from the 
body and this process is called “reverse cholesterol transport (RCT)” [5-7]. 
HDL formation and maturation is very important as they affect the efficiency of 
RCT pathway. Formation of nascent HDL begins with the association of apolipoprotein 
A1 (apoA-1), a major protein component of HDL particles consisting up to 70% of HDL 
proteins, with phospholipids and free cholesterol [8-10]. The formation of nascent HDL 
in the initial stage of RCT highly depends on the cholesterol efflux from intracellular 
spaces to extracellular acceptors via ATP binding cassette transporter A1 (ABCA1) [10, 
11]. ABCA1 promotes the efflux of cellular phospholipids and cholesterol to lipid-free 
apoA-I to form nascent HDL [10, 12]. On the other hand, maturation of HDL depends on 
cholesterol efflux from peripheral tissue and ATP binding cassette G1 (ABCG1) to 
mature HDL particle for further lipidation. Significant role of ABCG1 in cholesterol and 
lipid metabolism was supported by observations of a massive accumulation of cholesterol 
and neutral lipids in the macrophages and liver of Abcg1 knockout mice as well as a 
significant reduction in the cholesterol efflux to HDL when ABCG1 was knocked down 
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in macrophages by RNA interference [13, 14]. ABCA1 in the liver and intestine 
contribute to 80% and 20% of the HDL biogenesis, respectively, while cholesterol efflux 
in macrophages through ABCA1 and ABCG1 is important for cellular cholesterol 
homeostasis as well as inflammation[15].  
Fatty acids have been suggested to alter the expression of the ABC transporters.  
In particular, it has been shown that ABCA1 and ABCG1 expression is suppressed by 
unsaturated fatty acids (UFA), but not by saturated fatty acids in macrophages. In 
addition, patients with type 2 diabetes have 80% lower ABCG1 expression at both 
mRNA and protein levels in macrophages with impaired  cholesterol efflux to HDL [16]. 
The studies indicate an important link for the elevated CVD risk in type 2 diabetes where 
low plasma HDL cholesterol levels are commonly observed.  
The objective of this study was to elucidate molecular mechanisms for the 
regulation of ABCA1 and ABCG1 in HepG2, FHs 74Int cells and RAW264.7 
macrophages by fatty acids. The results of this study suggest that ABCA1 and ABCG1 
expression is repressed by unsaturated fatty acidsat the transcriptional as well as post-
transcriptional levels in a cell type-specific manner. 
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Literature Review 
 
I. Obesity and Chronic Disease, 
Obesity. Obesity is defined as a body mass index (BMI) of greater than 30.0 kg 
per m
2
. In 2007-2008, the age-adjusted prevalence of obesity in the United States was 
33.8% and the corresponding prevalence estimates for overweight and obesity combined 
were 68.0%[17].  
Numerous studies reported elevated lipid contents in the circulation in obesity 
contribute to the development of cardiovascular diseases (CVD) in 3 different ways: 
impaired insulin dependent glucose uptake, increased production of pro-inflammatory 
markers including C-reactive protein (CRP), interleukin-6 ( IL-6) and tumor necrosis 
factor-alpha (TNF-α), and alterations in secretion of adipose-derived signaling molecules 
called adipokines [2, 18]. Free fatty acids (FFA) and adipokines synthesized in 
adipocytes have been reported to play an important role in glucose homeostasis in the 
body [19].  In particular, studies have demonstrated that the elevated levels of circulating 
free fatty acids can cause peripheral insulin resistance in both animals and human while 
acute lowering of FFA enhanced glucose uptake in the insulin-dependent periphery tissue 
[19-23]. In addition, pro-inflammatory cytokines can interact with oxidized low density 
lipoprotein (Ox-LDL) and trigger a series of inflammatory responses within arterial wall, 
leading to the development of atherosclerosis[24]. Meanwhile, late observation of various 
pro-atherogenesis and also cardioprotective adipokines from different tissue including 
foam cells due to obesity might contribute to occurrence of CVD in obesity [25]. The 
close relationship between obesity and CVD is further evidenced by marked delay in the 
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development of type 2 diabetes and amelioration of CVD in obese subjects who take 
antiobesity agents and weight loss by 31 -53 percent compared to placebo[26, 27].  
 
CVD. CVD, as defined by the World Health Organization (WHO) as a group of 
cardiovascular disorders includes coronary heart disease (CHD), cerebrovascular disease, 
hypertension, peripheral artery disease, rheumatic heart disease, congenital heart disease 
and heart failure. According to the American Heart Association (AHA), there is a total of 
approximately 81.1 million of the population in the United States diagnosed at least one 
or more CVD in year 2006 [28]. Major risk factors for CVD are tightly linked to 
metabolic syndrome, which is a concurrence of disturbed glucose and
 
insulin metabolism, 
overweight and abdominal fat distribution (obesity),
 
dyslipidemia, and hypertension, as 
defined by thee WHO, National Cholesterol Education Program Adult Treatment Panel 
III (NCEP-APIII) and the International Diabetes Federation [29, 30]. Although the 
definition of metabolic syndrome is still in dispute among scholars and authoritative 
organizations, it is generally accepted that metabolic syndrome is close related to 
likelihood  of CVD development [31]. 
 
Type 2 Diabetes Mellitus.  American Diabetes Association reported a total of 3.6 
million children and adults or7.8% of the population in the United States are diabetic and 
diabetes was the seventh leading cause of death in 2006 [28]. In 2004, CVD was noted on 
68% of diabetes-related death certificates while 16% of diabetes-related death certificates 
were due to stroke among people aged 65 years or older [1, 2, 28]. Adults with diabetes 
have heart disease death rates and occurrence of stroke about 2 to 4 times higher than 
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adults without diabetes. By far, CVD is the most detrimental complication among all 
diabetes related complication among diabetic subjects [1].  
As a part of metabolic syndrome, development of type 2 diabetes occurs more 
prominently in obese subjects compared with lean individuals; however, genetic 
background and environmental predisposition such as physical inactivity are undeniable 
contributing factors to type 2 diabetes. Extensive accumulation of fat droplets in the 
adipocytes of obese subjects may lead to impaired responsiveness of skeletal muscle to 
insulin and failure of insulin secretion by pancreatic β cells [22]. Weight loss therapy 
coupled with drug therapy, such as metformin, a type of oral anti-hyperglycemic agent 
has been shown to efficiently maintaining euglycemia and hence prevent type 2 diabetes 
[27].  
Patients with diabetes and insulin resistance are at higher risk of developing CVD 
or CHD [32]. Excessive macronutrient intake especially foods rich in saturated fat and 
refined carbohydrates, has been shown to induced oxidative and inflammatory stress and 
to be associated with the induction of inflammation such as increased expression of 
suppressor of cytokine signaling-3 (SOCS-3), a mediator that interfers with insulin signal 
transduction [33]. 
 
II. Lipids and lipoprotein Metabolism. 
Dietary lipids. Several studies have shown that excessive intake of foods rich in 
saturated fatty acids induces oxidative and inflammatory stress by generating reactive 
oxygen species (ROS) while caloric restriction is effective in preventing 
inflammation[33].  
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Dietary lipids from both animal sources and plant sources abundantly contain 
triacylglycerols (TAGs) that consist of glycerol and saturated fatty acids (SFAs), 
monounsaturated fatty acids (MUFAs), polyunsaturated fatty acids (PUFAs), trans-fatty 
acids, phospholipids, and sterols. Both dietary cholesterol and denovo synthesized 
cholesterol are transported mainly in lipoproteins in the circulation. As the pre-cursor of 
bile acids, vitamin D and various hormones such as corticosteroids and sex hormones[15] 
, cholesterol is very crucial for normal physiological functions of the cells and endocrine 
system. In addition, fluidity and permeability of mosaic structure of cell membrane rely 
on cellular cholesterols level. 
 Approximately ~300-500mg of cholesterol is consumed per day from animal 
products while another 1000-1600mg per day of cholesterol is made by endogenous 
synthesis. VLDL contains 10–15% of the total serum cholesterol, LDL cholesterol 
typically makes up 60–70% of the total serum cholesterol while HDL cholesterol 
normally makes up 20–30 % of the total serum cholesterol [28]. 
Dyslipidemia is commonly observed in obese and diabetic patients and the 
subjects have elevated levels of plasma TAG, total cholesterol, LDL cholesterol and 
reduced high density liporprotein (HDL) cholesterol concentrations [26, 34].NCEP-APIII 
has defined dyslipidemia as having a total TAG levels of 150mg/dl or higher, total 
cholesterol levels of 200mg/dl or higher, LDL cholesterol 130mg/dl or higher, and HDL 
cholesterol of 40mg/dl or lower.  Plasma LDL cholesterol-lowering therapy with various 
drugs such as statins, HMG-CoA reductase inhibitors, can reduce incidence of CVD. In 
contrast, low plasma HDL cholesterol levels, which is inversely connected with the CVD 
risk, is another good predictor of CVD [28]. 
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Lipoproteins. Digested lipid component is absorbed in its simplest form into 
small intestine and packages into chylomicron, the largest lipoprotein in the circulation, 
to be transported in circulation. After chylomicrons losing TAG by lipoprotein lipase 
(LPL), resulting chylomicrons remnants are transported to the liver. In the liver, very low 
density lipoprotein (VLDL) is formed and functions to transport lipids in the circulation. 
VLDL becomes low density lipoprotein (LDL) after TAG in the particles is hydrolyzed 
by LPL. Most od LDL is recognized by LDL receptor (LDLR) primarily in liver and 
removed from the circulation. 
Chylomicrons are the largest but lowest density lipoproteins with a density of less 
than 0.95g/mL. Their major function is to transport dietary lipids, TAG in particular. 
Therefore, it is normally abundantly found in circulation at a postprandial state. It 
contains ~85% of TAG, 9% of phospholipids, 3% of cholesterol ester, 2% of protein, and 
1% of free cholesterol. Although apolipoprotein B-48 (apoB-48) is the main protein in 
chylomicron particles, chylomicrons also contain apoA-I, apoA-II, apoA-IV, apoC-I, 
apoC-II, apoC-III, and apoE. Chylomicrons leave enterocytes through lymphatic 
systemand by pass the hepatic portal vein. TAG in chylomicrons is generally used or 
stored in the peripheral tissues responsive to insulin. The chylomicron remnant is cleared 
from circulation to the liver.  
  VLDL is assembled in the live with apoB-100 and other lipids. It is the second 
largest lipoprotein class found in the human circulation, with a density of 0.95 to 1.006 
g/mL. It is a TAG-rich lipoprotein, containing 50% TAG, 18% phospholipid, 12% 
cholesteryl ester, 10% proteins and 7% free cholesterol. ATP III identifies elevated serum 
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VLDL cholesterol levels as a the surrogate marker for elevated atherogenic remnants in 
persons with triglycerides ≥200 mg/dL[28].  
LDL is the second smallest lipoprotein with a density of 1.019 to 1.063 g/mL. It 
contains 38% cholesteryl ester, 24% protein, 20% phospholipid, 8% free cholesterol and 
only 10% of TAG. The only apolipoprotein found in LDL particles is ApoB-100. 
Framingham Heart Study conducted by National Heart, Lung and Blood Institution 
demonstrated that high levels of plasma LDL cholesterol promote the development of 
CVD and atherosclerosis. The process is generally triggered by LDL oxidation in the 
intima of artery. Oxidation has a potential to make the apoB-100 undergo oxidative 
scission, further modify LDL confirmation, and disallow it to escape from intima [24]. 
HDL is the smallest and densest lipoproteins class found in the circulation. It 
participates in the RCT pathway that removes excess cholesterol from peripheral tissue to 
the liver for excetion from the body. It contains 55% of protein particles, 24% 
phospholipids, 15% cholesterol ester, 4% of TAG and only 2% of free cholesterol. The 
major apolipoproteins found in HDL particles are 75% apoA-I and 25% apoA-II, while 
the rest of the apolipoproteins are make up by apoA-IV, apoC-I, apoC-II, apoC-III and 
apoE [8, 35]. 
 The formation of nascent HDL is started from lipidation of lipid free apoA-I in a 
combination with phospholipid and cholesterol effluxed through ATP binding cassette 
transporter A1 (ABCA1). ApoA-1 knockout mice showed accelerated atherosclerosis 
development compared with wild-type mice while the opposite protective effect was 
found when ApoA-I was overexpressed in mice. Nascent HDL picks up more cholesterol 
from peripheral tissue via ABCA1 and ABCG1 in the peripheral tissues and become 
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mature. Several factors contribute to low HDL cholesterol levels including elevated 
serum TAG, overweight and obesity, physical inactivity, cigarette smoking, type 2 
diabetes, certain drugs and genetic factors. High HDL cholesterol levels are considered as 
a negative risk factor for CVD and has been suggested as a treatment goal in preventing 
CVD by ATP II [28]. 
 
III. Atherosclerosis and ATP Binding Cassette Transporters 
Development of Atherosclerosis. Among all types of CVD, atherosclerosis has 
raised most attention because it is highly related to dietary habits and lifestyle. 
Atherosclerosis is a condition pictured by narrowing of artery lumen due to a build-up of 
cholesterol-rich plaque in the intima of artery in respond to artery inflammation. The 
plaque contains soft, lipid-rich cores and when it ruptures, it is quickly covered by thin 
and inflammatory caps of fibrous tissues, causing a blockage of artery lumen in a very 
short time. This leads to death of acute coronary syndromes and strokes [36]. In general, 
atherogenesis happens in a normal physiological condition through out the lifespan. 
However, the prevalence has switched to younger generation in recent year [28]. In 
addition to dyslipidemia, other contributing factors to atherogenesis include gender, 
family history, cigarette smoking, hypertension, improper dietary intake, and physical 
inactivity. 
Atherogenesis is a multiple stages process. When excess LDL particles are 
circulating in the body, they tend to be oxidized in the intima of artery [24]. Minimally 
modified LDL can increase leukocyte-endothelial adhesion and secretion of monocyte 
chemotactic protein-1 (MCP-1) and stimulate transformation of monocyte to 
10 
 10 
macrophages [24, 34]. Other pro-inflammatory cytokines and molecules include CRP, 
interleukins (ILs), and TNF . OxLDL is not recognized by LDLR but it is taken up to the 
macrophages via the scavenger receptor. Cholesterol-loaded macrophages become foam 
cell and further trigger the migration of monocytes into intima, aggravating the foam cell 
formation [24]. Foam cells also contain small but significant amounts of various lipid 
oxidation products, which are potent mediators of macrophage function. 
 
Reverse Cholesterol Transport (RCT).  RCT is a vital process where excess free 
cholesterol is being transported from the peripheral tissues by HDL to the liver for 
secretion into bile and ultimate excretion from the body [7]. It is initiated when apoA-I 
interacts with serum phospholipids and free cholesterol via ABCA1 to form nascent 
HDL. Formation of nascent HDL triggers cholesterol efflux in the macrophages and other 
peripheral tissues via ABCA1 and ABCG1and eventually become mature HDL particles. 
Free cholesterol is normally esterified by lecithin:cholesterol acyltransferatse (LCAT) to 
be incorporated in the core of HDL. LCAT is necessary for extracellular cholesterol 
metabolism by facilitating cholesterol uptake into HDL in a more stable form and 
maintain a low plasma free cholesterol levels [37]. Phospholipid transfer protein (PLTP) 
is involved in the exchange of phospholipids between TAG-rich lipoproteins and HDL, 
contributing to transformation between HDL3 and HDL2. It has been reported that PLTP 
enzyme activity is higher in diabetic and obese patient and is correlated with high plasma 
TAG and low plasma HDL cholesterol levels[38]. Cholesterol ester transfer protein 
(CETP) allows exchange of cholesterol ester between HDL and LDL [7]. Up-regulation 
of the expression of macrophage ABCA1 and ABCG1 by activating liver X receptor 
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(LXR), a major transcription regulator for the ABC transporters, with its agonist is one 
way to increase RCT activity [39]. 
 
ATP binding Cassette transporter A1 and G1.  There are at least 48 ABC 
transporter proteins have been recognized and categorized into seven families from A to 
G according to their sequence, functions, locations and similarities [40].Some of them are 
involved in lipid transport and ABC A transporters and ABC G transporters are most 
well-known for lipid transportand metabolism. [40] 
 ABCA1 is a LXR responsive gene and plays a critical role in cholesterol efflux 
from cells to extracellular acceptors such as lipid free apoA-1, forming nascent HDL [7]. 
It is a 240 kDa protein and a full transporter with 12 membrane spanning domains. 
ABCA1 is regulated when LXR α or β binds to LXR responsive element in the ABCA1 
promoter together with an obligate heterodimer partner retinoid X receptor (RXR) [39]. 
Mutations in ABCA1 result in Tangier disease, a severe HDL deficiency characterized by 
accumulation of cholesterol in tissues rich in macrophages due to the impaired ability of 
cholesterol efflux [6, 41, 42]. The Tangier patients are generally diagnosed with pre-
mature atherosclerosis. ABCA1 is highly expressed in most of cell types, including 
hepatocytes, enterocytes, adipocytes, skeletal muscle cells and macrophages.  
ABCG1 plays an important role in cholesterol efflux to mature HDL particles, 
which is a key step in the RCT pathway for the prevention of atherosclerosis. It is a half 
size transporter and therefore has to form a homodimer or heterodimer with another 
ABCG transporter to be functional [40]. In general, the molecular weight of ABCG1 is 
about 70 kDa  [13]. Studies have shown that macrophages with knockdown of ABCG1 
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have a significant reduction in cholesterol efflux to HDL [43]. Abcg1 knockout mice 
exhibited massive accumulation of cholesterol in the macrophages and lung when they 
were fed a high fat-high cholesterol diet compare to the wild-type [14]. In addition, 
cholesterol efflux to HDL was increased in wild type mouse macrophages by T0901317, 
an LXR agonist, but not in abcg1 knockout macrophages [14].  
Patients with type 2 diabetes have 80% lower ABCG1 expression at both mRNA 
levels and protein level in macrophages with impaired  cholesterol efflux to HDL [16]. 
ABCG1 is regulated by cellular cholesterol content, evidenced by an increased 
expression in both mRNA and protein levels in the present of acetylated LDL, and down-
regulation with HDL3 treament in monocyte-derived macrophages [13, 44]. 
Expression of ABCA1 and ABCG1 is very important in HDL formation as well 
as cellular cholesterol homeostasis. Elevated cholesterol level within cells has been 
shown to upregulate the expression of ABCA1 and ABCG1 and vice versa [45]. Up-
regulation of ABCA1 and ABCG1 expression can be achieved by the activation of LXR, 
which is confirmed by the observations that expression of ABCA1 and ABCG1 was 
elevated by LXR agonists in various cell lines [39]. Moreover, LXR agonists contribute 
to redistribution of ABCG1 from intracellular membrane to the plasma membrane, 
consequently facilitating cholesterol efflux [39]. Endotoxin, an LXRα down-regulator, 
has been shown to decrease mRNA and protein expression of ABCA1 and ABCG1 [46]. 
In addition, ABCA1 and ABCG1 expression is also positively induced by peroxisome 
proliferator-activated receptor (PPAR), fibric acids, cyclic AMP phosphorylated protein 
kinase A (cAMP/PKA) pathway in a LXR/RXR-dependent or independent manner [39]. 
Recent studies indicate that PEST sequence in murine ABCA1 is responsible for its 
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phosphorylation and thus promote protein degradation in a calpain dependent manner 
[45, 47]. 
ABCA1 is shown to be regulated by fatty acids at both transcription and post-
transcription levels. Studies have shown that unsaturated fatty acids repress the 
expression of ABCA1 by increasing protein degradation via the activation of 
phospholipase D2 (PLD2) and subsequent phosphorylation on serine residues by protein 
kinase C (PKC) delta [12, 48, 49].  
Increased ABCA1 mRNA and protein expression has been shown in human 
monocyte-derived macrophages in the present of acetyl salicylic acid (ASA, aspirin), 
indicating a potential role of ABCA1 in preventing arterial inflammation [36].  
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 Post-transcriptional regulation of ATP-binding cassette 
transporter A1 (ABCA1) expression by unsaturated 
fatty acids in HepG2 and FHs 74 Int cells  
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1.1 Abstract 
ATP binding cassette transporter A1 (ABCA1) plays a critical role in the 
formation and metabolism of high-density lipoproteins (HDL). ABCA1 in the liver and 
small intestine, in particular, accounts for ~90% of plasma HDL cholesterol. Therefore, 
any alterations in the hepatic and intestinal expression of ABCA1 could have a large 
impact on HDL biogenesis. We investigated the modulation of ABCA1 expression by 
fatty acids in vitro using human hepatoma HepG2 and human small intestine epithelial 
FHs 74 Int cells. The cells were incubated with saturated and unsaturated fatty acids in 
the presence or absence of T0901317, a synthetic agonist of liver X receptor (LXR). 
Unsaturated fatty acids reduced ABCA1 protein levels at 100 M of concentration 
regardless of the agonist with a minimal effect on mRNA abundanceIncubation of HepG2 
and FHs 74 Int cells with rottlerin, a protein kinase C  (PKCδ) inhibitor, increased 
ABCA1 protein in all treatments tested, but did not abolish linoleic acid (18:2)-induced 
reduction in ABCA1 protein levels. Depletion of PKC  using small interfering RNA 
showed a reduction in ABCA1 protein levels in control, palmitic acid (16:0) and 18:2-
treated cells, but it further aggravated the repressive effect of 18:2 on ABCA1 protein in 
HepG2 cells. The reduced ABCA1 protein levels by 18:2 were not abolished by 
calpeptin, an inhibitor of calpain protease. In conclusion, our results indicate that 
unsaturated fatty acids regulate ABCA1 expression in HepG2 and FHs 74 Int cells at the 
post-transcriptional level in a calpain protease-independent manner. PKC  is likely to be 
involved in maintaining ABCA1 protein levels and potentially prevents a reduction in the 
protein level by unsaturated fatty acids.      
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1.2 Introduction 
ATP-binding cassette transporter A1 (ABCA1) is a membrane transporter that 
mediates the efflux of phospholipid and free cholesterol to lipid-free or lipid-poor 
apolipoprotein A-I (apoA-I), the major protein constituent in high-density lipoprotein 
(HDL) particles, contributing to HDL biogenesis [1-3]. The significant role of ABCA1 in 
HDL metabolism is underscored by the finding that mutations in Abca1 gene lead to near 
absence of plasma HDL cholesterol concentrations in patients with Tangier disease and 
familial HDL deficiencies [4]. Studies on targeted inactivation of Abca1 in mice also 
support the role of ABCA1 in the efflux of phospholipid and free cholesterol and HDL 
formation [5, 6]. In particular, deletion of Abca1 in the liver and intestine reduced plasma 
HDL cholesterol concentrations by ~80% and ~30%, respectively, indicating that 
ABCA1 in these tissues are quantitatively most important for maintaining plasma HDL 
cholesterol levels [7, 8].  
Transcription of ABCA1 is under the control of liver X receptor (LXR), a major 
transcription factor for genes important in cholesterol metabolism in response to cellular 
cholesterol levels [9]. In addition to transcriptional regulation by cholesterol, ABCA1 
expression can also be regulated transcriptionally by fatty acids. In human macrophages, 
ABCA1 expression was lower in 18:2-treated cells than cells incubated with 16:0 [10]. 
ABCA1 mRNA levels in HepG2 and RAW 264.7 macrophages were decreased by 
unsaturated fatty acids with a reduction in ABCA1 promoter activity [11]. Mutations or 
deletion of direct repeat 4, the LXR/retinoid X receptor (RXR) heterodimer binding 
element, in the promoter of Abca1 abolished the suppressive effects of unsaturated fatty 
acids on ABCA1 expression [12]. These studies indicate unsaturated fatty acids, but not 
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saturated fatty acids, reduced ABCA1 expression by inhibiting the binding of LXR/RXR 
heterodimers to the Abca1 promoter. Post-transcriptional regulation of ABCA1 by 
unsaturated fatty acids in macrophages has also been demonstrated. Wang and Oram [13-
16] found that unsaturated fatty acids increased ABCA1 protein degradation in 
macrophages by activating phospholipase D2 (PLD2) and subsequently protein kinase C  
(PKC ), which in turn phosphorylates ABCA1 serine residues for protein degradation. In 
Caco-2 cells, post-transcriptional regulation of ABCA1 expression by unsaturated fatty 
acids was also suggested with a modest fatty acid-induced suppression of the gene 
transcription [17].   
Individuals with obesity and type 2 diabetes are at high risk of cardiovascular disease 
(CVD) [18-25]. Particularly, lowered plasma HDL cholesterol concentrations by ~15-30% in type 
2 diabetic individuals are associated with an increased risk of CVD in this population [26, 27]. As 
epidemiological studies have consistently shown a strong inverse relationship between plasma 
HDL cholesterol concentrations and the incidence of CVD [26-28], the reduced plasma HDL 
cholesterol levels in diabetic subjects could contribute to their increased CVD risk. HDL can 
deliver excess cholesterol from the periphery to the liver for ultimate excretion from the body. 
This process called “reverse cholesterol transport (RCT)” is believed to be a major athero-
protective property of HDL [29-31]. Therefore, any disturbance in this process could facilitate 
cholesterol accumulation and foam cell formation in the arterial wall, a primary hallmark of 
atherosclerosis. High plasma free fatty acid concentrations are typically associated with obesity, 
insulin resistance and type 2 diabetes [32-36] and are known to have a large impact on insulin 
resistance and diabetic dyslipidemia [37-47]. In particular, increased free fatty acid flux to the 
liver contributes to hepatic insulin resistance [40-42], increased glucose output [48], steatosis [37] 
and high triglyceride secretion in very-low density lipoproteins [37, 43].  
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Given the significant role of hepatic and intestinal ABCA1 in the HDL biogenesis, 
understanding of the effect of fatty acids on ABCA1 in these tissues is important to determine 
perturbed HDL metabolism in pathological conditions such as type 2 diabetes. This study was 
undertaken to evaluate the effect of various fatty acids on the expression of ABCA1 in the liver 
and intestine using in vitro cell models, i.e., HepG2, a human hepatoma cell line, and FHs 74 Int 
cells, a human small intestine epithelial cell line. We found that ABCA1 expression in HepG2 
and FHs 74 Int cells was post-transcriptionally repressed by unsaturated fatty acids in a calpain 
protease-independent manner. Our data also suggest that PKC  may play an important role in 
maintaining ABCA1 protein levels and inhibit the repressive effect of unsaturated fatty acids on 
ABCA1 protein expression.  
 
1.3 Materials and Methods 
1.3.1 Cell culture and fatty acid preparation 
HepG2 cells and FHs 74 Int cells were purchased from ATCC (Manassas, VA). 
The cells were maintained in Minimal Essential Medium containing 10% fetal bovine 
serum (FBS), 100 U/ml penicillin, 100 g/ml streptomycin, 1 x vitamins and 2 mM L-
glutamine in a humidified chamber at 37
o
C with 5% CO2. For FHs 74 Int cells, 30 ng/ml 
epidural growth factor and 10 g/ml insulin were additionally supplemented to cell 
culture medium. All cell culture supplies were purchased from MediaTech (Manassas, 
VA). 
Two mM of fatty acid-poor and endotoxin-free bovine serum albumin (BSA) 
(EMD Chemicals, Gibbston, NJ) was prepared in phosphate buffered saline (PBS). 
Sodium salts of fatty acids (Nu-Chek, Elysian, MN) were dissolved in the 2 mM BSA 
solution to a final concentration of 5 mM. The fatty acid and BSA mixture was purged 
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with N2 and sonicated in warm water bath (~40
o
C) until the solution became clear to 
form BSA/fatty acid complex (a molar ration to BAS of 1:2.5). The complex was filter 
sterilized and diluted with cell medium to reach a final concentration of 100 M of fatty 
acid and incubated in a water bath for 1 hr prior to be added to cells. HepG2 cells were 
incubated with or without 10 M of T0901317 (Sigma-Aldrich, St. Louis, MO), a LXR 
agonist, in dimethyl sulfoxide (DMSO) for 18 hrs, after which cells were treated with 
BSA only (control) or 100 M of a fatty acid for 12 hrs. Cells were also incubated with 
BSA or 100 M fatty acids (16:0 or 18:2) for 6 hrs and subsequently with 5 or 10 M 
rottlerin (Santa Cruz Biotechnology, Santa Cruz, CA), a PKC  inhibitor, in DMSO for an 
additional 6 hrs. Rottlerin (PKC  inhibitor; 5 or 10 M in DMSO; Santa Cruz 
Biotechnology, Santa Cruz, CA) and calpeptin (calpain protease inhibitor; 20 g/ml in 
DMSO; MP Biomedicals, Solon, OH) were used to inhibit the respective enzyme. For the 
experiments with inhibitors, cells were preincubated with an inhibitor for 2 hrs, and 
subsequently with 100 M of fatty acid for 12 hrs. Control cells were incubated with the 
same amount of DMSO for a vehicle control. Cells were cultured in complete medium 
devoid of FBS when they were treated with fatty acid to eliminate any potential 
contamination of fatty acids present in FBS 
 
1.3.2 Small Interfering RNA (siRNA) Transfection 
To knockdown PKC , HepG2 cells were transfected with Silencer  Negative 
Control scrambled siRNA (Ambion, Austin, TX) or siGENOME  PKC  siRNA (Thermo 
Scientific, Pittsburgh, PA) using a transfection reagent DharmaFECT1 (Thermo 
Scientific) according to the manufacturer’s protocol. In brief, 5 l of DharmaFECT1 was 
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diluted into 195 l of cell medium void of antibiotics and FBS. Scrambled control and 
PKC  siRNA (2 M) were prepared in RNase-free sterile water and 100 l of the 2 M 
siRNA solution was mixed with 100 l of cell medium void of antibiotics and FBS. 
Subsequently, the media containing transfection agent and siRNA (200 l each) were 
combined and incubated for 20 min at room temperature. The siRNA and transfection 
agent complex was then diluted to 2 ml with cell medium and added into a 6 well plate, 
24 hrs after which cells were washed twice with PBS and treated with BSA or 100 M of 
fatty acid for 24 hrs. 
 
1.3.3 Total RNA Isolation and Quantitative Realtime PCR 
Total RNA was extracted from cells using TRIzol reagent (Invitrogen, Carlsbad, 
CA) following manufacturer’s protocol. Reverse transcription for cDNA synthesis and 
quantitative realtime PCR analysis were performed as previously described [49, 50]. 
Primers were designed according to GenBank database using the Primer Express 
software (Applied Biosystems, Austin, TX). The following primers were used for 
realtime PCR analysis: ABCA1, forward (5’-CGTTTCCGGGAAGTGTCCTA-3’), 
reverse (5’-GCTAGAGATGACAAGGAGGATGGA-3’); glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH), forward (5’-GTGGTCTCCTCTGACTTCAACA-3’), reverse 
(5’-GTTGCTGTAGCCAAATTCGTTGT-3’)   
 
1.3.4 Western Blot Analysis 
Cell lysate was prepared and Western blot analysis was performed as previously 
described [49, 50]. Rabbit anti-ABCA1 antibody was a generous gift from Dr. John Parks 
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at Wake Forest University School of Medicine and PKCδ antibody was purchased from 
Santa Cruz Biotechnology (Santa Cruz, CA). -actin (Sigma-Aldrich, St. Louis, MO) was 
used as a loading control to normalize the data. 
 
1.3.5 Statistical Analysis 
 ANOVA and Tukey’s pairwise comparison with Welch’s correction for unequal 
variance when appropriate were used to identify statistically significant differences of 
treatments with P < 0.05 considered significant by GraphPad InStat 3 (GraphPad 
Software Inc., La Jolla, CA). Data are expressed as mean  SEM. 
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1.4 Results 
1.4.1 Down-regulation of ABCA1 protein levels by unsaturated fatty acids 
HepG2 cells were treated with various fatty acids in the presence or absence of 
T0901317. In the absence of the LXR agonist, ABCA1 mRNA abundance was not 
significantly different in all of fatty acid treated cells compared with control (Figure 1A). 
T0901317 markedly increased ABCA1 mRNA levels by ~7-25-fold. Saturated and 
monounsaturated fatty acids minimally altered ABCA1 mRNA whereas significantly 
higher mRNA levels were observed in cells treated with poly unsaturated fatty acids, i.e., 
oleic acid (18:1), 18:2 and eicosapentaenoic acid (20:5), than control. However, ABCA1 
protein (~250 Kda) was noticeably reduced by unsaturated fatty acids tested, i.e., 18:1, 
18:2 and 20:5, compared with control and saturated fatty acid-treated cells irrespective of 
the presence of T0901317 (Figure 1B). In particular, polyunsaturated fatty acids reduced 
ABCA1 protein levels to the greatest extent. Similar results were observed in FHs 74 Int 
cells (Figure 2A & B). 
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Figure 1 Unsaturated fatty acids inhibited ABCA1 expression at the post-transcriptional 
level in HepG2 cells. Cells were incubated with or without a LXR agonist T0901317 (10 
M) for 18 hrs and subsequently with BSA only (control) or fatty acids (100 M) 
complexed with BSA for 12 hrs. A. ABCA1 mRNA abundance by quantitative realtime 
PCR. Values are Means ± SEM, n = 6. Bars without a common letter are significantly 
different, P < 0.05. B. ABCA1 protein by Western blot analysis with -actin as a loading 
control. A representative blot of two separate experiments is shown. Densitometry 
analysis was conducted using -actin for normalization and ABCA1 protein expression 
levels relative to control without T0901317 treatment are shown as numbers below the 
gel image. Values of two lanes of the same treatment are averaged. 
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Figure 2 Unsaturated fatty acids inhibited ABCA1 expression at the post-transcriptional 
level in FHs 74 Int cells. Cells were without or with T0901317 (10 M) for 18 hrs and 
subsequently with BSA only (control) or fatty acids (100 M) complexed with BSA for 
12 hrs. A. ABCA1 mRNA abundance by quantitative realtime PCR. Values are Means ± 
SEM, n = 6. Bars without a common letter are significantly different, P < 0.05. B. 
ABCA1 protein of cells treated with fatty acids in the presence of T0901317 is visualized 
by Western blot analysis with -actin as a loading control. A representative blot of two 
separate experiments is shown.     
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1.4.2 Involvement of PKCδ in the post-transcriptional regulation of ABCA1 expression 
by fatty acids 
Degradation of ABCA1 is an important regulatory mechanism for its activity [51, 
52]. Post-transcriptional regulation of ABCA1 by unsaturated fatty acids is suggested to 
result from destabilization of ABCA1 protein through its phosphorylation by PKC  in 
macrophages [16]. To evaluate if the same mode of action exists in HepG2 and FHs 74 
Int cells, cells were incubated with 16:0 or 18:2 in the presence of 5 or 10 mol/L of 
rottlerin, a PKC  inhibitor. Although rottlerin tended to increase ABCA1 protein in most 
treatments, it did not abolish the repressive effect of 18:2 on ABCA1 protein in HepG2 
cells (Figure 3A) and FHs 74 Int cells (Figure 3B). To further verify the involvement of 
PKCδ in the degradation of ABCA1 protein by unsaturated fatty acids, HepG2 cells were 
transfected with control scrambled or PKCδ siRNA to knockdown PKC  and 
subsequently, the cells were incubated with 16:0 and 18:2. Depletion of PKC  by ~70-
90% by siRNA was not able to abolish the repressive effect of 18:2 on ABCA1 protein 
and even aggravated the inhibition (Figure 4). Interestingly, knockdown of PKC  
reduced ABCA1 protein in all treatments, suggesting that PKC  might play a role in 
maintaining ABCA1 protein levels. 
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Figure 3 Rottlerin increased ABCA1 protein but could not reverse unsaturated fatty 
acid-induced down-regulation of ABCA1 protein expression in HepG2 and FHs 74 Int 
cells. HepG2 (A) and FHs 74 Int (B) cells were preincubated with rottlerin (5 and 10 M) 
for 2 hrs, after which they were treated with BSA only (control), 16:0 or 18:2 (100 M) 
for 12 hrs. ABCA1 protein expression was measured by Western blot analysis using -
actin as a loading control. A representative blot of two separate experiments is shown 
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Figure 4 Depletion of PKC  failed to abolish reduced ABCA1 protein levels by 
unsaturated fatty acids in HepG2 cells. Cells were transfected with 100 nM of scrambled 
control (Sc) or PKCδ siRNA for 24 hrs and subsequently incubated with BSA only 
(control), 16:0 or 18:2 (100 M) for 24 hrs. ABCA1 and PKCδ protein levels were 
determined by Western blot analysis using -actin as a loading control. A representative 
blot of two separate experiments is shown 
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1.4.3 Role of calpain protease in the modulation of ABCA1 protein levels by fatty acids 
Phosphorylation in the PEST sequence of ABCA1 is shown to increase ABCA1 
protein degradation by calpain protease [53, 54]. To assess whether this mechanism is 
involved in reduced ABCA1 protein levels by unsaturated fatty acids, HepG2 cells were 
treated with calpeptin, a calpain inhibitor. Although calpeptin induced a general increase 
in ABCA1 protein levels, it could not reverse reduced ABCA1 protein by 18:2 (Figure 5), 
suggesting that repressed ABCA1 protein by unsaturated fatty acids is not likely calpain 
protease-dependent. 
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Figure 5 Inhibition of calpain protease did not reverse the repressive effect of 
unsaturated fatty acids on ABCA1 protein in HepG2 cells. Cells were preincubated with a 
calpain inhibitor calpeptin (20 g/ml) for 2 hrs and subsequently treated with BSA only 
(control) or 100 M of 16:0 or 18:2 for 12 hrs. Western blot analysis was conducted for 
ABCA1 and -actin 
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1.5 Discussion 
Obesity and type 2 diabetes are currently significant health issues in the United 
States and other Westernized countries. Of the various complications associated with type 
2 diabetes, CVD is the leading cause of morbidity and mortality in diabetic subjects with 
2-8-fold higher risk than the non-diabetic population [55-57]. Although low plasma HDL 
cholesterol concentrations in obese and diabetic individuals could be a major mediator for 
atherogenesis, the mechanisms underlying perturbed HDL metabolism are not clearly 
understood. As increased plasma free fatty acid concentrations and influx into tissues 
have been suggested to play a role in diabetic dyslipidemia [32-34, 37-39] and ABCA1 in 
the liver and intestine is the major factor to maintain plasma HDL cholesterol levels [7, 
8], our current study was undertaken to investigate the effect of fatty acids on the hepatic 
and intestinal ABCA1 expression. We found that unsaturated fatty acids, polyunsaturated 
fatty acids in particular, repressed ABCA1 expression in HepG2 and FHs 74 Int cells at 
the post-transcriptional level in a calpain-protease independent manner. In addition, our 
data suggest that PKC  could play an important role in maintaining ABCA1 protein 
expression and potentially inhibit down-regulation of the protein by unsaturated fatty 
acids.       
ABCA1 facilitates the efflux of phospholipid and free cholesterol to lipid-free or 
lipid-poor apoA-I, which is the critical step for HDL biogenesis [2, 3]. In vitro interaction 
of apoA-I with ABCA1 produces heterogeneous-sized, pre-  HDL subpopulations which 
have a different metabolic fate depending on the degree of lipidation, with less lipidated 
HDL being rapidly removed by kidney [58, 59]. Tissue site of ABCA1 expression is also 
important for the production of HDL as dysfunctional ABCA1 in the liver and intestine 
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led to reduced plasma HDL cholesterol concentrations by ~80% and ~30%, respectively 
[7, 8]. Studies using animal models of Tangier disease, such as the WHAM chicken and 
Abca1
-/-
 mice, support that apoA-I secretion from the liver and intestine is not rate 
limiting in HDL formation, but rather modifications in apoA-I after secretion are 
important in maintaining plasma HDL cholesterol levels [5, 60]. Additionally, initial 
lipidation of apoA-I via the interaction with ABCA1 is shown to be a critical preliminary 
step in HDL formation presumably by producing nascent HDL [61, 62]. The studies 
emphasize a pivotal role of ABCA1 in HDL biogenesis by lipidating newly-secreted 
apoA-I in the liver and intestine, which are exclusive sites of apoA-I secretion. 
Accordingly, lack of interaction of apoA-1 with ABCA1 in the liver and intestine due to 
diminished ABCA1 expression could possibly lower the production of nascent HDL, 
consequently reducing plasma HDL cholesterol levels. In the present study, ABCA1 
protein levels were significantly lowered by unsaturated fatty acids, but not by saturated 
fatty acids, without reducing its mRNA abundance in HepG2 and FHs 74 Int cells. The 
post-transcriptional inhibition of ABCA1 expression has also been shown in 
macrophages [13, 14], HepG2 [11] and Caco-2 cells [17]. Considering the critical role of 
hepatic and intestinal ABCA1 in HDL biogenesis, the diminished ABCA1 expression by 
unsaturated fatty acids could have a negative impact on plasma HDL cholesterol 
concentrations.     
Although much attention has been given to the changes in plasma total and low-
density lipoprotein (LDL) cholesterol concentrations in response to dietary fatty acids, 
studies have shown that dietary fatty acids can alter plasma HDL cholesterol levels. 
Isocaloric substitution of n-3 polyunsaturated fatty acids for saturated fatty acids 
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decreased plasma concentrations of total cholesterol, LDL cholesterol and HDL 
cholesterol in non-human primates [63] and humans [64]. African green monkeys fed 
atherogenic diets containing polyunsaturated fatty acids had significantly decreased 
plasma concentrations of total cholesterol, HDL cholesterol and apoA-I compared with 
saturated and monounsaturated fatty acids-fed animals [65]. In addition, a recent study in 
humans reported that plasma HDL cholesterol concentrations were lower when subjects 
were on a polyunsaturated fatty acid-rich diet compared with a saturated fatty acid-rich 
diet [66]. Therefore, studies exist to support a HDL cholesterol-lowering effect of 
unsaturated fatty acid, and polyunsaturated fatty acids in particular, relative to saturated 
fatty acids. We found that all unsaturated fatty acids reduced ABCA1 protein levels in 
HepG2 cells, but polyunsaturated fatty acids, such as 18:2 and 20:5, induced the greatest 
reduction. Our data suggest that the decreased plasma HDL cholesterol concentrations by 
unsaturated fatty acids compared with saturated fatty acids could be, at least in part, 
attributed to diminished hepatic and intestinal ABCA1 expression, lowering nascent HDL 
formation.   
Turnover of ABCA1 protein is rapid with a half-life of less than 1 h in murine 
macrophage-like cells and differentiated THP-1 cells [52, 67], suggesting that post-
transcriptional regulation could be an important determinant for its function. Unsaturated 
fatty acids, but not saturated fatty acids, were shown to increase ABCA1 protein 
degradation in macrophages and baby hamster kidney cells by activating PLD2 and 
subsequently PKC , which resulted in the serine phosphorylation and destabilization of 
ABCA1 [15, 16]. However, we found that neither rottlerin nor depletion of PKC  by 
siRNA abolished the repressive effect of 18:2 on ABCA1 protein levels in HepG2 and 
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FHs 74 Int cells. Instead, rottlerin treatment tended to increase the transporter protein 
whereas PKC  knockdown lowered protein levels independent of types of fatty acids. In 
addition, PKC  siRNA treatment aggravated the repressive effect of 18:2 on ABCA1 
protein levels in HepG2 cells. Our results indicate that PCK  is not involved in 
facilitating ABCA1 protein degradation by unsaturated fatty acids in HepG2 and FHs 74 
Int cells. Rather, PKC  is likely to play a role in maintaining ABCA1 protein expression 
and inhibition of PKC  could be involved in reduced ABCA1 protein levels by 
unsaturated fatty acids. The reasons for the contradictory observations between our 
results and previously reported data are not clear. However, as we found the similar 
response in RAW 264.7 macrophages (unpublished data), we do not think the 
contradiction is due to different cell types used in two studies. More investigation is 
necessary to explain the differences.  
Although rottlerin has been widely used as  a selective PKC  inhibitor, there is a 
recent debate on its selectivity for PKC  as it inhibits other kinases [68]. Increased 
ABCA1 expression by rottlerin but decreased expression by PKC  siRNA shown in our 
study favor that rottlerin is not a PKC -specific inhibitor. Phosphorylation of ABCA1 
can alter its protein degradation or activity depending on sites of phosphorylation. 
Phosphorylation in the PEST sequence of ABCA1 is shown to increase the protein 
degradation by calpain [53, 54] whereas ABCA1 protein levels are positively correlated 
to its phosphorylation in THP-1 cells [51]. Given that rottlerin treatment enhanced 
ABCA1 proteins, we speculate that kinases susceptible to the inhibition by rottlerin could 
be present to lower ABCA1 protein in HepG2 and FHs 74 Int cells. Identification of the 
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kinases and phosphorylation sites in ABCA1 is important to increase ABCA1 expression 
and consequently plasma HDL cholesterol concentrations.      
Phosphorylation of Thr-1286 and Thr-1305 in the PEST sequence of ABCA1 
increases protein degradation by calpain [53, 54]. In the present study, although calpeptin 
increased ABCA1 protein levels, it could not reverse the reduced ABCA1 protein by 
18:2. This suggests that protein degradation by unsaturated fatty acids may not be a 
calpain protease-dependent. Interestingly, ABCA1 is known to be ubiquitinated and 
lactacystin, a proteosome inhibitor, increased the protein in macrophages [53, 69], 
suggesting that a proteasomal degradation pathway exists for ABCA1 protein. Whether 
this mechanism is involved in the post-transcriptional regulation of ABCA1 by 
unsaturated fatty acids in HepG2 and FHs 74 Int cells needs to be further investigated. In 
summary, the present study demonstrated that unsaturated fatty acids lower ABCA1 
expression in HepG2 and FHs 74 Int cells. The inhibition by unsaturated fatty acids could 
have a large impact on HDL formation, lowering plasma HDL cholesterol concentrations. 
As plasma HDL cholesterol levels are inversely related to the risk of CVD, one could 
argue that the potential unfavorable effect of unsaturated fatty acid on ABCA1 
contradicts a well-known athero-protective role of unsaturated fatty acids, 
polyunsaturated fatty acids in particular, compared with saturated fatty acids. Athero-
protection of polyunsaturated fatty acids, however, is attributable to their effects on very-
low density lipoprotein, LDL and triglyceride metabolism, anti-inflammation and anti-
thrombosis [63, 70-72]. These benefits could override the inhibition of hepatic and 
intestinal ABCA1 expression by polyunsaturated fatty acids in protecting against 
atherosclerosis. The repressive effect of unsaturated fatty acids on ABCA1 expression 
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has a particular health implication in obese and type 2 diabetic subjects, whose plasma 
free fatty acids are commonly elevated. Increased fatty acid influx into tissues consequent 
to high plasma fatty acid levels is known to perturb various metabolic pathways related to 
insulin resistance and diabetic dyslipidemia. Proper dietary interventions for the 
pathological conditions require our better understanding of the modulation of ABCA1 
expression by fatty acids. 
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 Repression of ATP binding cassette transporter A1 
(ABCA1) and ABCG1 expression by unsaturated fatty 
acids in RAW 264.7 macrophages  
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2.1 Abstract 
Reverse cholesterol transport (RCT), a process to deliver excess cholesterol from 
the periphery to the liver for ultimate excretion from body, is a major athero-protective 
property of high-density lipoproteins. As major transporters for cholesterol efflux in 
macrophages, ATP-binding cassette transporter A1 (ABCA1) and ABCG1 play a pivotal 
role in the RCT. We investigated molecular mechanisms for the regulation of ABCA1 
and ABCG1 expression by fatty acids in RAW 264.7 macrophages. Cells were incubated 
with fatty acids including palmitic (16:0), oleic (18:1), linoleic (18:2), linolenic (18:3), 
eicosapentaenoic (20:5) and docosahexaenoic (22:6) acid in the absence or presence of 
T0901317, a liver X receptor (LXR) agonist.. Unsaturated fatty acids (UFA), but not 
saturated fatty acids, significantly reduced ABCA1 and ABCG1 mRNA levels in the 
absence of the LXR agonist. The repression by UFA, however, was abolished by 
T0901317, suggesting a potential LXR-dependent repression of basal ABCA1 and 
ABCG1 expression by UFA. Treatment with trichostatin A, a histone deacetylase 
inhibitor, not only increased the basal ABC transporter expression but abrogated the 
transcriptional repression by UFA. Although repressive effect of ABCA1 and ABCG1 
mRNA by UFA was abolished by T0901317, protein levels remained diminished by 
UFA, which suggests post-transcriptional repression of the ABC transporters by UFA. 
Chemical and genetic deficiency of protein kinase  (PKC ) potentiated the repressive 
effect of 18:0 on ABCA1 and ABCG1. Calpeptin, a calpain protease inhibitor, could not 
counteract 18:2-induced repression of the protein levels. In conclusion, UFA diminished 
ABCA1 and ABCG1 expression in macrophages by two distinct mechanisms in RAW 
264.7 macrophages: LXR-dependent transcriptional repression of basal expression 
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possibly via modifications in histone acetylation state; and calpain-independent post-
transcriptional inhibition.
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2.2 Introduction 
Dyslipidemia, an underlying condition for several chronic diseases such as 
coronary heart disease (CHD) and type 2 diabetes, is characterized by high plasma 
concentrations of total cholesterol, low-density lipoprotein (LDL) cholesterol and 
triglycerides as well as low plasma high-density lipoprotein (HDL) cholesterol levels (1). 
Since the hypothesis that high levels of plasma HDL cholesterol are protective against 
CHD was initially proposed in the early 1950s (2), epidemiological studies have 
consistently shown a strong inverse relationship between plasma HDL cholesterol levels 
and the incident of CHD (3-6). The anti-atherogenic effect of HDL is due in part to the 
ability of HDL to promote cholesterol efflux from cells and to participate in reverse 
cholesterol transport (RCT) (7-9). In the RCT, excess cholesterol is transported from the 
periphery to the liver for ultimate excretion from body and HDL function as the primary 
acceptor of cellular free cholesterol (10).  
Removal of cholesterol from macrophages present in arterial wall via the RCT is 
of significant importance in the prevention of atherosclerosis development. ATP binding 
cassette transporter A1 (ABCA1) and ABCG1 play a pivotal role in this process. ABCA1 
facilitates the efflux of cellular cholesterol to extracellular acceptors, namely lipid-free or 
lipid-poor apolipoprotein A-I (11-14). In contrast, ABCG1 is highly expressed in 
macrophages and mediates the efflux of cholesterol to HDL2 (15, 16). Deletion of 
macrophage Abcg1 led to the deposition of FC and cholesteryl esters in various tissues, 
implicating its role in maintaining cellular cholesterol level (17, 18). Studies have shown 
that dysfunction of ABCA1 and ABCG1 in macrophages induces cholesterol 
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accumulation and accelerates atherosclerosis although some contradictory observations 
exist as to the role of ABCG1 in atherogenesis (19-23).   
Transcription of ABCA1 and ABCG1 is primarily under the control of liver X 
receptors (LXR) in response to cellular cholesterol levels (24). Studies have shown that 
fatty acids can alter ABCA1 expression at the transcriptional and post-transcriptional 
levels. Post-transcriptional repression of ABCA1 expression by unsaturated fatty acids in 
macrophages has been demonstrated by a series of studies conducted by Wang and Oram 
(25-28). In their studies, unsaturated fatty acids increase ABCA1 protein degradation in 
macrophages by activating phospholipase D2 (PLD2) and subsequently protein kinase C  
(PKC ). This, in turn, phosphorylates ABCA1 serine residues for protein degradation. 
Despite post-transcriptional regulation of ABCA1 by unsaturated fatty acids 
demonstrated by Wang and Oram, others have shown that fatty acids could alter 
transcription of ABCA1 and ABCG1. In human macrophages, ABCA1 and ABCG1 
mRNA levels were lowered by linoleic acid compared with palmitic acid (29). ABCA1 
mRNA abundance in HepG2 and RAW 264.7 macrophages was reduced by unsaturated 
fatty acids with diminished ABCA1 promoter activity (30). Mutations or deletion of 
direct repeat 4, a cis-acting element for LXR binding, in the promoters of ABCA1 and 
ABCG1 abolished the suppressive effects of unsaturated fatty acids on their transcription 
(31). These studies suggest that unsaturated fatty acids reduced the ABC transporter 
expression by an LXR-dependent mechanism.  
Although studies have demonstrated that unsaturated fatty acids, but not saturated 
fatty acids, reduce ABCA1 and ABCG1 expression. However, limited and contradictory 
observations exist as to the molecular mechanisms underlying the repressive effect of 
51 
 
unsaturated fatty acids. This study was conducted to gain an insight into mechanisms 
underlying the modulation of ABCA1 and ABCG1 expression by fatty acids in RAW 
264.7 macrophages. We found that unsaturated fatty acids repress the ABC transporters 
in macrophages at both transcriptional and post-transcriptional levels. 
 
2.3 Materials and Methods 
2.3.1 Cell culture and fatty acid preparation 
Raw 264.7 macrophages were purchased from ATCC (Manassas, VA) and 
maintained in RPMI medium containing 10% fetal bovine serum (FBS), 100 U/mL 
penicillin, 100 g/ml streptomycin, 1x vitamins and 2 mmol/L L-glutamine in a 
humidified incubator at 37
o
C with 5% CO2.   
Stock solution (2 mmol/L) of fatty acid-poor and endotoxin-free bovine serum 
albumin (BSA) (EMD Chemicals, Gibbston, NJ) was prepared in PBS. Sodium salts of 
fatty acids (Nu-Chek, Elysian, MN) were dissolved in the BSA stock solution to a final 
concentration of 5 mmol/L. The fatty acid and BSA mixture was purged with N2 and 
sonicated in warm water bath (~40
o
C) until the solution became clear to form BSA/fatty 
acid complex (a molar ratio to BSA of 1:2.5). The complex was then filter sterilized and 
diluted with cell medium to reach a final concentration of 100 mol/L of fatty acid and 
incubated in a water bath at 37
o
C for 1 hr prior to addition to cells.   
RAW264.7 macrophages were incubated without or with 10 mol/L T0901317 
(Sigma-Aldrich, St. Louis, MO), an LXR agonist, in DMSO or 18 hrs, after which cells 
were treated with BSA only (control) or 100 mol/L of fatty acid for 12 hrs. Rottlerin 
(PKC  inhibitor; 5 or 10 M in DMSO; Santa Cruz Biotechnology, Sata Cruz, CA) and 
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calpeptin (calpain protease inhibitor; 20 g/ml in DMSO; MP Biomedicals, Solon, OH) 
were used to inhibit the respective enzyme. For the experiments with inhibitors, cells 
were preincubated with an inhibitor for 2 hrs, and subsequently with 100 mol/L of fatty 
acid for 12 hrs. Control cells were incubated with the same amount of DMSO as a vehicle 
control. For experiments with trichostatin A (TSA), a pan-histone deacetylase inhibitor 
(HDACi), RAW 264.7 macrophages were incubated with 100 mol/L fatty acid in the 
absence or presence of 500 nmol/L of TSA for 24 hrs. To evaluate protein degradation, 
RAW 264.7 macrophages were treated with BSA control or 100 mol/L of 18:2 for 2 hrs, 
after which 20 g/ml cycloheximide in DMSO (Acros, Thermo Fisher Scientific), a 
translation inhibitor, was added to halt protein synthesis.  Cells were cultured in complete 
medium devoid of FBS when they were treated with fatty acid to eliminate any potential 
contamination of fatty acids present in FBS. 
 
2.3.2 Small Interfering RNA (siRNA) Transfection 
RAW 264.7 macrophages were transfected with Silencer  Negative Control 
scrambled siRNA (Ambion, Austin, TX) or siGENOME  PKC  siRNA (Thermo 
Scientific, Pittsburgh, PA) to knockdown PKC  using DharmaFECT1 transfection 
reagent (Thermo Scientific) according to the manufacturer’s protocol. In brief, 5 l of 
DharmaFECT1 was diluted into 195 l of cell medium void of antibiotics and FBS. 
Scrambled control and PKC  siRNA (2 mol/L) were prepared in RNase-free sterile 
water and 100 l of the 2 mol/L siRNA solution was mixed with 100 l of cell medium 
void of antibiotics and FBS. Subsequently, the media containing transfection agent and 
siRNA (200 l each) were combined and incubated for 20 min at room temperature. The 
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siRNA and transfection agent complex was then diluted to 2 ml with cell medium and 
added into a 6 well plate, 24 hrs after which cells were washed twice with PBS and 
treated with BSA or 100 mol/L of fatty acid for 24 hrs. 
 
 
54 
 
Table 2.1 Real-time PCR primers for gene expression analysis                                           
Gene Forward Primer Reverse Primer 
ABCA1 5’- CGTTTCCGGGAAGTGTCCTA -3’ 5’- GCTAGAGATGACAAGGAGGATGGA -3’ 
ABCG1 5’- AGGTCTCAGCCTTCTAAAGTTCCTC -3’ 5’- TCTCTCGAAGTGAATGAAATTTATCG -3’ 
LXR  5’- CGACAGAGCTTCGTCCACAA -3’ 5’- ACAGCTCGTTCCCCAGCAT-3’ 
PPAR  5’- GCCCACCAACTTCGGAATC -3’ 5’- TGCGAGTGGTCTTCCATCAC -3’ 
PGC-1  5’- AAGCTGAAGCCCTCTTGCAA -3’ 5’- ACTGTACCGGGCCCTCTTG -3’ 
PGC-1  5’- CGCTCCAGGAGACTGAATCCAGT -3' 5’ -CTTGACTACTGTCTGTGAGGC -3’ 
GAPDH 5’- TGTGTCCGTCGTGGATCTGA -3’ 5’- CCTGCTTCACCACCTTCTTGAT -3’ 
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2.3.3 Total RNA Isolation and Quantitative Realtime PCR 
Total RNA was extracted from cells using TRIzol reagent (Invitrogen, Carlsbad, 
CA) following manufacturer’s protocol. Reverse transcription for cDNA synthesis and 
quantitative realtime PCR analysis were performed as previously described (32, 33). 
Primers were designed according to GenBank database using the Primer Express 
software (Applied Biosystems, Austin, TX). Lists of primer sequence are available as 
Online Supporting Material with the online posting of this paper at http://jn.nutrition.org. 
 
2.3.4 Western Blot Analysis 
Cell lysate was prepared and Western blot analysis was performed as previously 
described (32, 33). Rabbit ABCA1 anti-serum was a generous gift from Dr. John Parks at 
Wake Forest University School of Medicine.  Rabbit ABCG1 antibody was purchased 
from Novus Biologicals (Littleton, CO) and PKCδ antibody was obtained from Santa 
Cruz Biotechnology (Santa Cruz, CA). Monoclonal antibody against -actin was 
purchased from Sigma-Aldrich (St. Louis, MO) and used as a loading control to 
normalize the data. 
2.3.5 Statistical Analysis 
 ANOVA and Tukey’s pairwise comparison with Welch’s correction for unequal 
variance when appropriate were used to identify statistically significant differences of 
treatments with P < 0.05 considered significant by GraphPad InStat 3 (GraphPad 
Software, Inc.).  Data are expressed as mean  SEM. 
  
2.4 Results 
2.4.1 Macrophage ABCA1 and ABCG1 expression was repressed by unsaturated fatty 
acids 
To gain an insight into the modulation of macrophage ABCA1 and ABCG1 
expression by fatty acids, RAW 264.7 macrophages were treated with various fatty acids 
including 16:0, 16L1, 18:1, 18:2, 18:3 and 20:5 in the absence or presence of T091317, 
an LXR agonist. In the absence of the LXR agonist, both ABCA1 and ABCG1 mRNA 
levels were significantly repressed by all the unsaturated fatty acids tested compared with 
the control (Figure 1A). However, when T0901317 was present, the repressive effect 
was completely abolished, suggesting the transcriptional repression of the ABC 
transporters by unsaturated fatty acids in macrophage is presumed to be LXR-dependent. 
ABCA1 (~250 KDa) and ABCG1 (~60 KDa) protein levels were also markedly reduced 
by unsaturated fatty acids in the absence of T0901317 in consistent with mRNA levels 
(Figure 1B). Unsaturated fatty acids, however, were able to lower the ABC transporter 
protein levels when the cells were treated with the LXR agonist despite no changes in 
mRNA abundance were observed. The data indicates a potential LXR-independent 
repression of ABCA1 and ABCG1 by unsaturated fatty acids expression at the post-
transcriptional level. 
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Figure 1 Regulation of ABCA1 and ABCG1 expression by fatty acids in RAW 264.7 
macrophages. Cells were incubated with or without a LXR agonist T0901317 (10 M) 
for 18 hrs and subsequently with BSA only (control) or fatty acids (100 M) complexed 
with BSA for 12 hrs. A. ABCA1 mRNA abundance by quantitative realtime PCR. Values 
are Means ± SEM, n = 6. Bars without a common letter are significantly different, P < 
0.05. B. ABCA1 protein by Western blot analysis with -actin as a loading control. A 
representative blot of two separate experiments is shown. 
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1.4.2 Inhibition of histone deacetylase (HDAC) abolished the repressive effect of 
unsaturated fatty acids on ABCA1 and ABCG1 mRNA levels 
Alterations in chromatin structure are an important way to regulate gene 
transcription. To evaluate a potential involvement of modulations in histone acetylation 
status in the unsaturated fatty acid-induced transcriptional repression of macrophage 
ABCA1 and ABCG1, RAW 264.7 macrophages were incubated with 16:0 and 18:2 in the 
presence of trichostatin A (TSA), a pan-histone deacetylase inhibitor (HDACi). In 
consistent with the previous observation shown in Figure 1, without TSA, both ABCA1 
and ABCG1 mRNA levels were significantly repressed by 18:2 (Figure 2). However, 
when the macrophages were treated with TSA, mRNA levels of ABCA1 and ABCG1 
was significantly increased and furthermore the repression by 18:2 was completely 
abolished.  It is of interest that in the presence of TSA, 16:0-treated cells showed 
significantly lower ABCA1 and ABCG1 mRNA abundance than control and 18:2-treated 
cells.  
TSA treatment altered the expression of other genes that have been linked to the 
regulation of ABCA1 and ABCG1 transcription. Whereas peroxisome proliferator-
activated receptor  (PPAR ) and PPAR  coactivator 1  (PGC-1 ) expression was 
significantly increased by TSA along with ABCA1 and ABCG1, LXR  and PGC-1  
mRNA levels were significantly decreased by TSA (Figure 3). 
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Figure 2 Effect of TSA on ABCA1 and ABCG1 expression in RAW 264.7 macrophages. 
The cells were incubated with 500 nmol/L TSA for 20 hrs together with fatty acids (100 
M) complexed with BSA. mRNA abundance was measured by quantitative realtime 
PCR. Means ± SEM, n = 6-13. *, P < 0.05 vs. control (-TSA). #, P < 0.05 vs. control 
(+TSA). 
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Figure 3 Effect of TSA on the expression of genes related to transcriptional 
regulation of ABC transporters in RAW 264.7 macrophages. The cells incubated TSA 
and fatty as described in figure 2 were analyzed by realtime PCR. Means ± SEM, n = 6-
13. 
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2.4.3 Rottlerin did not abolish the unsaturated fatty acids-induced reduction in ABCA1 
and ABCG1 proteins 
Macrophage ABCA1 and ABCG1 protein levels were diminished by unsaturated 
fatty acids even with LXR activation in the condition which the repression was abolished. 
Post-transcriptional regulation of ABCA1 by unsaturated fatty acids was suggested to 
result from destabilization of ABCA1 protein through its phosphorylation by PKC  
pathway (28). To evaluate a role of PKC  in the fatty acid regulation of ABCA1 as well 
as ABCG1 protein levels, we incubated RAW 264.7 macrophages with 16:0 or 18:2 in 
the presence of rottlerin, a commonly used PKC  inhibitor, or after depletion of PKC  
using siRNA. In contrast to the previous report in literature (28), neither rottlerin nor 
PKC  siRNA abolished the repressive effect of 18:2 on ABCA1 and ABCG1 proteins  in 
the macrophages (Figure 4A and 4B). Instead, rottlerin treatment and PKC  deficiency 
potentiated the repressive effect of 18:2. 
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Figure 4 Role of PKC  in ABCA1 and ABCG1 protein levels in RAW 264.7 
macrophages. (A) Cells were pre-incubated with rottlerin (5 and 10 M) for 2 hrs, after 
which they were treated with BSA only (control), 16:0 or 18:2 (100 M) for 12 hrs. 
ABCA1 and ABCG1 protein expression was measured by Western blot analysis using -
actin as a loading control. A representative blot of two separate experiments is shown. 
(B) Cells were transfected with 100nM of scrambled control (Sc) or PKCδ siRNA for 24 
hrs and subsequently incubated with BSA only (control), 16:0 or 18:2 (100 M) for 24 
hrs. ABCA1, ABCG1 and PKCδ protein levels were determined by Western blot analysis 
using -actin as a loading control. A representative blot of two separate experiments is 
shown 
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2.4.4 Enhanced ABCA1 protein degradation by unsaturated fatty acids is calpain-
independent 
Degradation of ABC transporter proteins is an important regulatory means for 
their activity (34, 35). To assess whether reduced ABCA1 protein levels by unsaturated 
fatty acids is due, at least in part, to increased protein degradation, RAW 264.7 
macrophages were treated with cycloheximide, a translation inhibitor, together with 18:2. 
ABCA1 protein degradation was faster by 18:2 compared with controls (Figure 5A).    
Phosphorylation of PEST sequence in ABCA1 protein is shown to increase the protein 
degradation by calpain protease (36, 37). To assess whether calpain is involved in the 
protein degradation of ABCA1 and ABCG1 by fatty acids, RAW 264.7 macrophages 
were treated with calpeptin, a calpain inhibitor. Although calpeptin induced a general 
increase in ABCA1 and ABCG1protein levels, it could not reverse reduced protein levels 
by 18:2, suggesting that the ABC transporter protein degradation by unsaturated fatty 
acids is not a calpain protease-dependent (Fig 5B). 
 
 
 
 
 
 
 
 
 
64 
 
 
 
Figure 5  Inhibition of calpain protease did not reverse the repressive effect of 
unsaturated fatty acids on ABCA1 protein in HepG2 cells. (A) Cells were treated with 
BSA control or 100 mol/L of fatty acids for 2 hrs and subsequently 20 g/ml 
cycloheximide was added. Cellular proteins were obtained 0, 0.5, 1, 2 and 3 hrs after the 
addition of cycloheximide for Western blot analysis. (B) RAW 264.7 macrophages were 
preincubated with a calpain inhibitor calpeptin (20 g/ml) for 2 hrs and subsequently 
treated with BSA only (control) or 100 M of 16:0 or 18:2 for 12 hrs. Western blot 
analysis was conducted for ABCA1 and -actin. 
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2.5 Discussion 
ABCA1 and ABCG1 in macrophages play a pivotal role in maintaining cellular 
cholesterol homeostasis by effluxing cholesterol to extracellular acceptors such as lipid-
free or lipid-poor apoA-I and HDL, respectively. Therefore, disturbance of the ABC 
transporter functions in macrophages, particularly in the arterial wall, could facilitate 
foam cell formation and consequently atherogenesis. Elevated plasma free fatty acid 
concentrations in obesity have been associated with insulin resistance and type 2 diabetes 
(38-42). As cardiovascular disease is the leading cause of morality and mortality among 
complications associated with type 2 diabetes (43-45), it is critical to understand 
mechanisms for accelerated atherosclerosis development by diabetic factors. The goal of 
this study was to understand molecular regulatory mechanisms for the regulation of 
macrophage ABCA1 and ABCG1 by fatty acids. We found that expression of ABCA1 
and ABCG1 in macrophages are repressed by unsaturated fatty acids via two distinct 
mechanisms, i.e., LXR-dependent transcriptional repression and increased calpain-
independent protein degradation.  
Several studies have reported that fatty acids modulate the expression of ABCA1 
and ABCG1 (25-31, 46, 47). The detailed regulatory mechanisms, however, remain 
largely enigmatic and contradictory. We observed that unsaturated fatty acids repressed 
mRNA abundance of ABCA1 and ABCG1 in RAW 264.7 macrophages and the 
repression was abolished by an LXR agonist. The data indicate unsaturated fatty acids 
may inhibit the basal expression of the ABC transporters possibly in an LXR-dependent 
manner in macrophages. Involvement of LXR in the transcriptional repression of ABCA1 
and ABCG1 in macrophages was also suggested by Uehara et al. (30, 31). Of importance 
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is that unliganded LXR is suggested to repress the basal expression of the ABC 
transporters by recruiting co-repressors, such as nuclear receptor corepressor (NCoR) and 
silencing mediators for retinoid and thyroid hormone receptors (SMRT), in macrophages 
but not in the liver (48). As we observed the transcriptional repression of the basal 
ABCA1 expression by unsaturated fatty acids only in macrophages but not in HepG2 
cells (manuscript in preparation), it can be presumed that unsaturated fatty acids could 
enhance recruitment of the co-repressor complex to unliganded LXR and/or its activity in 
the promoters of macrophage ABCA1 and ABCG1.  
Exchange of co-repressor with co-activator is widely used to switch function of 
transcription factors from active repression to transcriptional activation. Transcription 
factors that have been shown to interact with a co-repressor complex for transcriptional 
repression include activator protein 1 (49-51), nuclear factor B (50-52), thyroid 
hormone receptor (53-55) and LXR  (48). NCoR and SMRT are essential components of 
co-repressor complex and mediate active transcriptional repression via activating histone 
deacetylase (HDAC) in the complex (49, 56, 57). HDAC3 is known to regulate ABCA1 
and ABCG1 expression as a component of a co-repressor complex containing 
NCoR/SMRT (48, 58). Interestingly, we found that TSA, a pan-HDACi, markedly 
increased the ABC transporter mRNA and abolished the repressive effect of unsaturated 
fatty acids on the transporter expression in RAW 264.7 macrophages. The result suggests 
that basal transcription of ABCA1 and ABCG1 may be repressed by a HDAC and 
unsaturated fatty acid could further inhibit the transcription by modulating histone 
deacetylation in the promoters of the ABC transporters.  Several lines of evidence exist to 
support potential roles of fatty acids, such as short-chain FA (e.g., butyrate) and 9-
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hydroxystearic acid, in modulating chromatin structure (59, 60). However, whether fatty 
acids commonly present in the diet could utilize this mode of transcriptional regulation is 
largely unknown. It should be further investigated whether long-chain fatty acids utilize 
HDAC to alter gene expression.  
Turnover of ABCA1 protein is rapid with a half-life of less than 1 hr in 
macrophages (35, 61), suggesting that post-transcriptional regulation could be an 
important determinant for its function. We found that unsaturated fatty acids reduced 
ABCA1 and ABCG1 protein levels in macrophages. Although T0901317 abolished the 
repression of the ABC transporter mRNA levels by unsaturated fatty acids, protein levels 
of both transporters remained to be diminished by unsaturated fatty acids compared with 
saturated fatty acids, suggesting that post-transcriptional repression of ABCA1 and 
ABCG1 is likely to exist in addition to the transcriptional inhibition. Reduced ABCA1 
protein levels by 18:2 were at least partly due to faster protein degradation as 
demonstrated by the experiment using cycloheximide. It has been suggested that 
unsaturated fatty acids induce ABCA1 protein degradation by activating PLD2 and PKC  
pathway that phosphorylates serine residues of ABCA1 for degradation (25-28). We, 
however, found PKC  may function in an opposite direction as its depletion by siRNA 
and chemical inhibition using rottlerin reduced ABCA1 and ABCG1 proteins and failed 
to reverse the repressive effect of unsaturated fatty acids. The reason for the contradictory 
observations is not clear and further study is necessary to identify the role of PKC  in the 
post-transcriptional regulation of the ABC transporters by fatty acids.  
Studies have shown that phosphorylation of ABCA1 can alter its protein 
degradation or activity depending phosphorylation sites. ABCA1 protein levels are 
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positively correlated to its phosphorylation in THP-1 cells (34). In contrast, 
phosphorylation of Thr-1286 and Thr-1305 in the PEST sequence of ABCA1 increases 
the protein degradation by calpain (36, 37). When calpain protease was inhibited by 
calpeptin in our study, 18:2 was still able to lower ABCA1 and ABCG1 protein levels in 
RAW 264.7 macrophages, suggesting that elevated the protein degradation by 18:2 may 
not be mediated through calpain. ABCA1 is known to be ubiquitinated and lactacystin, a 
proteosome inhibitor, increased the protein in macrophages (36, 62), suggesting that a 
proteasomal degradation pathway exists for ABCA1 protein. Whether this mechanism is 
involved in the post-transcriptional regulation of ABCA1 and ABCG1 by unsaturated 
fatty acids in RAW 264.7 macrophages needs to be further investigated.   
In summary, we found that unsaturated fatty acids repress the expression of 
ABCA1 and ABCG1 in macrophages at the transcription and post-transcription levels. As 
macrophage ABCA1 and ABCG1 play a pivotal role in removal of cellular cholesterol, 
which can prevent foam cell formation, the inhibitory function of unsaturated fatty acids 
in the transporter expression could have a negative impact on atherogenesis. One could 
argue that the potential unfavorable effect of unsaturated fatty acid on ABCA1 and 
ABCG1 contradicts a well-known athero-protective role of unsaturated fatty acids, 
polyunsaturated fatty acids in particular, compared with saturated fatty acids. Athero-
protection of polyunsaturated fatty acids, however, is attributable to their effects on very-
low density lipoprotein, LDL and triglyceride metabolism, anti-inflammation and anti-
thrombosis (63-66). These benefits could override the inhibition of ABCA1 and ABCG1 
expression by unsaturated fatty acids in protecting against atherosclerosis. Understanding 
of mechanisms by which fatty acids modulate the ABC transporters in macrophages is 
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necessary to develop a therapeutic means to enhance beneficial effect of unsaturated fatty 
acids in the prevention of atherosclerosis development. 
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